

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 19 SEP 2005 HIGHEST RN 863478-08-4
 DICTIONARY FILE UPDATES: 19 SEP 2005 HIGHEST RN 863478-08-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.


```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

Experimental and calculated property data are now available. For more information enter HELP PROP at an arrow prompt in the file or refer to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-649208.str



chain nodes :

17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 36 38

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

4-21 5-17 6-30 7-33 8-34 9-20 10-31 11-32 12-36 14-22 15-29 17-18 17-19
 19-20 22-23 23-24 23-38 24-25 25-26 25-27 25-28

ring bonds :

1-2 1-6 2-3 2-13 3-4 3-15 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14
 14-15

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-21 5-6 12-36 17-18 17-19 19-20 22-23 23-24 23-38
 25-27 25-28

exact bonds :

2-13 3-15 5-17 6-30 7-33 8-34 9-20 10-31 11-32 13-14 14-15 14-22 15-29
24-25 25-26

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:Cl,Br,F,CN

G2:CH3,Et

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:Atom 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 33:CLASS 34:CLASS 36:CLASS 38:CLASS

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



G1 Cl,Br,F,CN

G2 Me,Et

Structure attributes must be viewed using STN Express query preparation.

=> s l1 ful

FULL SEARCH INITIATED 15:48:42 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 157 TO ITERATE


100.0% PROCESSED 157 ITERATIONS
SEARCH TIME: 00.00.01

0 ANSWERS

L2 0 SEA SSS FUL L1

=>

Uploading C:\Program Files\Stnexp\Queries\10-649208a.str



chain nodes :

17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 34 36

ring nodes :

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

chain bonds :

4-21 5-17 6-28 7-31 8-32 9-20 10-29 11-30 12-34 14-22 15-27 17-18 17-19
19-20 22-23 23-24 23-36 24-25 25-26

ring bonds :

1-2 1-6 2-3 2-13 3-4 3-15 4-5 5-6 7-8 7-12 8-9 9-10 10-11 11-12 13-14
14-15

exact/norm bonds :

1-2 1-6 2-3 3-4 4-5 4-21 5-6 12-34 17-18 17-19 19-20 22-23 23-24 23-36
25-26

exact bonds :

2-13 3-15 5-17 6-28 7-31 8-32 9-20 10-29 11-30 13-14 14-15 14-22 15-27
24-25

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

G1:Cl,Br,F,CN


G2:CH3,Et

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS 27:CLASS 28:CLASS
29:CLASS 30:CLASS 31:CLASS 32:CLASS 34:CLASS 36:CLASS

L3 STRUCTURE UPLOADED

=> d
 L3 HAS NO ANSWERS
 L3 STR



G1 Cl,Br,F,CN

G2 Me,Et

Structure attributes must be viewed using STN Express query preparation.

=> s l3 ful
 FULL SEARCH INITIATED 15:49:55 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 158 TO ITERATE

100.0% PROCESSED 158 ITERATIONS
 SEARCH TIME: 00.00.01

97 ANSWERS

L4 97 SEA SSS FUL L3

=> fil caplus
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
323.09	323.30

FILE 'CAPLUS' ENTERED AT 15:49:58 ON 20 SEP 2005
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Sep 2005 VOL 143 ISS 13
FILE LAST UPDATED: 19 Sep 2005 (20050919/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l4

L5 7 L4

=> d ibib abs hitstr tot

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2004:1059360 CAPLUS
 DOCUMENT NUMBER: 142:38231
 TITLE: Preparation of thienopyridine-ethanolamine derivatives
 as antiviral agents
 INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Eggen, Marijean;
 Anderson, David J.; Judge, Thomas M.; Kim, Ruibong J.;
 Collier, Sarah A.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 95 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106345	A2	20041209	WO 2003-US24802	20030827
WO 2004106345	A3	20050303		


W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MM, MG, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CB, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-408067P P 20020904

OTHER SOURCE(S): MARPAT 142:38231
 GI

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




AB Title compds. I [wherein R1 = Cl, Br, F or cyano; R2 = (un)substituted alkyl or (CH2)mOCH2CH2OH; R3 = Cl-2 alkyl; R4 = five-membered N/O/S(O)m-heteroaryl optionally fused to benzene or pyridine ring; R5 = H or Cl-2 alkyl optionally substituted with OH; m = 1 or 2, and stereoisomers or pharmaceutically acceptable salts thereof] were prepared. For example, II was synthesized as a racemate in several steps.


Resolution and further purification gave (R)-II isomer. This isomer showed inhibitory activity against HCMV, HSV and VZV polymerases with IC50 (μM) values of 0.04, 0.09 and 0.03, resp. Therefore, I and pharmaceutical compns. thereof are useful as as herpesviral DNA polymerase inhibitors, and as antiviral agents, in particular, as agents against viruses of the herpes family.

IT 804510-51-8P 804511-05-5P, Rac-N-(4-Chlorobenzyl)-2-[[[2-hydroxy-2-((1H-pyrazol-3-yl)ethyl)(methylamino)methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)
 RN 804510-51-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[[4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804511-05-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[[4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)



IT 804510-54-1P 804510-57-4P 804510-60-9P
 804510-63-2P 804510-66-5P 804510-69-8P
 804510-72-3P 804510-75-6P 804510-81-4P
 804510-84-7P 804510-87-0P 804510-90-5P
 804510-93-8P 804510-96-1P 804510-99-4P
 804511-02-2P 804511-08-8P, N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-11-3P, N-(4-Chlorobenzyl)-7-ethyl-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-17-9P

hydroxyethyl(methylamino)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-14-6P, N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl(methylamino)methyl]-7-(2-methoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-17-9P
 804511-20-4P 804511-23-7P 804511-29-3P
 804511-35-1P 804511-41-9P 804511-47-5P
 804511-50-0P 804511-57-7P 804511-66-8P
 804511-69-1P, N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl(methylamino)methyl]-4-oxo-7-propyl-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-78-2P, N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl(methylamino)methyl]-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-84-0P

(5-chloro-2-furanyl)-2-hydroxyethyl(methylamino)methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-84-0P
 N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl(methylamino)methyl]-7-(2-hydroxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-96-4P, N-(4-Chlorobenzyl)-2-[[[2-(2-furanyl)-2-hydroxyethyl(methylamino)methyl]-7-(2-hydroxyethoxyethyl)-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide 804511-99-7P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


(Uses)
 (drug candidate; prepn. of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)

RN 804510-54-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[[4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 804510-57-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[[4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)




RN 804510-60-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[[[4-chlorophenyl)methyl]-2-[[[2-(2-furanyl)-2-hydroxyethyl)methylamino)methyl]-4,7-dihydro-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (9CI) (CA INDEX NAME)




RN 804510-63-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl(methylamino)methyl]-N-[[[4-chlorophenyl)methyl]-4,7-dihydro-7-


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 804510-66-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-thienyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-69-8 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-72-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-pyrrol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804510-87-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(2,5-dimethyl-3-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-90-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzo(b)thien-3-yl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-93-8 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-indol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804510-75-6 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-methyl-1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-81-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-84-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-indol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804510-96-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(5-cyano-2-thienyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804510-99-4 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-thiazolyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-02-2 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzothiazolyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 804511-08-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(1H-pyrazol-3-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-11-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-14-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 804511-29-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 804511-35-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-41-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


Absolute stereochemistry.



RN 804511-17-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-20-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 804511-23-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804511-47-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-50-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-57-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 804511-66-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(5-phenyl-2-furanyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-69-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-propyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-78-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(5-chloro-2-furanyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




IT 804510-78-9P 804511-26-0P 804511-32-8P
 804511-38-4P 804511-44-2P 804511-81-7P
 804511-93-1P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (hydroxyethyl)aminomethyl dihydrothienopyridines as antiviral agents)

RN 804510-78-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1-(triphenylmethyl)-1H-imidazol-4-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-26-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)




RN 804511-32-8 CAPLUS

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)




RN 804511-84-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-hydroxyethyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-96-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-(2-hydroxyethoxy)ethyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-99-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(1H-imidazol-2-yl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS ON STN (Continued)


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-38-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2R)-2-(2-furanyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 804511-44-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, 2-[[[2-(2-benzofuranyl)-2-hydroxyethyl]methylamino]methyl]-N-[(4-chlorophenyl)methyl]-4,7-dihydro-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 804511-81-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide,
 N-[(4-chlorophenyl)methyl]-2-[[[(2R)-
 2-(2-furanyl)-2-hydroxyethyl)methylamino]methyl]-4,7-dihydro-4-oxo-7-[2-
 [(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 804511-93-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide,
 N-[(4-chlorophenyl)methyl]-2-[[[(2R)-
 2-(2-furanyl)-2-hydroxyethyl)methylamino]methyl]-4,7-dihydro-4-oxo-7-[2-
 [(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220341 CAPLUS
 DOCUMENT NUMBER: 140:270842
 TITLE: Preparation of arylethanol(thienopyridinemethyl)amine derivatives as antiviral agents
 INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Ciske, Fred L.; Genin, Michael J.; Anderson, David J.; Judge, Thomas W.; Eggen, Marijean; Collier, Sarah A.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022568	A1	20040318	WO 2003-US24807	20030827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, BO, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG				
US 2004116464	A1	20040617	US 2003-649202	20030827
US 2005049245	A1	20050303	US 2003-649208	20030827
PRIORITY APPLN. INFO.:			US 2002-408206P	P 20020904

OTHER SOURCE(S): MARPAT 140:270842
 GI



AB Arylethanol(thienopyridinemethyl)amine derivative of formula I [R1 = halo, CN; R2 = (substituted) alkyl, etc.; R3 = alkyl; R4 = H, (substituted) alkyl; Ar = (substituted) Ph, aryl] are prepared as antiviral agents, in particular, as agents against viruses of the herpes family. Thus, II was


L5 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


prepd., and had IC50 of 0.05 μM against HCMV polymerase.
 IT 672325-77-8P 672325-86-9P 672325-93-8P
 672325-95-0P 672325-97-2P 672325-98-3P
 672325-99-4P
 RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of arylethanol(thienopyridinemethyl)amine deriva. as antiviral agents)
 RN 672325-77-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-hydroxyphenyl)ethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672325-86-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(3-methoxyphenyl)ethyl)methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-93-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide,
 N-[(4-chlorophenyl)methyl]-2-[[[(2S)-
 2-(4-cyanophenyl)-2-hydroxyethyl)methylamino]methyl]-4,7-dihydro-7-methyl-
 4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672325-95-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-

2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672325-97-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[(2S)-


2-(4-(dimethylamino)phenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672325-98-3 CAPLUS

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 672325-81-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672325-82-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(3-hydroxypropyl)-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672325-84-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-(hydroxymethyl)phenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-99-4 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 672325-79-0P 672325-81-4P 672325-82-5P
 672325-84-7P 672325-88-1P 672325-90-5P
 672325-91-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of aryethanol(thienopyridinemethyl)amine deriva. as antiviral agents)

RN 672325-79-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672325-88-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-90-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672325-91-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2S)-2-hydroxy-2-phenylethyl]methylamino]methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



IT 292144-13-9
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); PROC (Process)
 (preparation of aryethanol(thienopyridinemethyl)amine deriva. as antiviral agents)


RN 292144-13-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-38-4P 672326-39-5P 672326-40-8P
 672326-41-9P 672326-42-0P 672326-43-1P
 RL: PEP (Physical, engineering or chemical process); PYP (Physical process); SPN (Synthetic preparation); PREP (Preparation); PROC (Process)
 (preparation of aryethanol(thienopyridinemethyl)amine deriva. as antiviral agents)

RN 672326-38-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(3-methoxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672326-42-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-(hydroxymethyl)phenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

—OH


PAGE 1-B

RN 672326-43-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-nitrophenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




IT 672326-26-0P 672326-28-2P 672326-29-3P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of aryethanol(thienopyridinemethyl)amine deriva. as antiviral agents)


L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672326-39-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672326-40-8 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(3-cyanophenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672326-41-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-2-[[[2-(4-(dimethylamino)phenyl)-2-hydroxyethyl]methylamino]methyl]-4,7-dihydro-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


RN 672326-26-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-4,7-dihydro-2-[[[2-(2-hydroxy-2-phenylethyl)methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672326-28-2 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-(2-hydroxy-2-phenylethyl)methylamino]methyl]-4-oxo-7-[3-[(tetrahydro-2H-pyran-2-yl)oxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 672326-29-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-(2-hydroxy-2-phenylethyl)methylamino]methyl]-4-oxo-7-[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:220340 CAPLUS
DOCUMENT NUMBER: 140:270841

TITLE: Preparation of heteroarylethanamines as antiviral agents
INVENTOR(S): Fleck, Thomas J.; Schnute, Mark E.; Cudahy, Michele M.; Anderson, David J.; Judge, Thomas M.; Herrington, Paul M.; Mair, Sajiv K.; Scott, Allen; Perrault, William R.; Tanis, Steven P.; Nieman, James A.; Collier, Sarah A.


PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA; Fleck, Bruce Francis
SOURCE: PCT Int. Appl., 90 pp.

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022567	A1	20040318	WO 2003-US24806	20030827
N: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZH, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004110787	A1	20040610	US 2003-649301	20030827
PRIORITY APPL. INFO:		US 2002-408065P	P	20020904

OTHER SOURCE(S): MARPAT 140:270841
G1



AB Title compds. [I; R1 = Cl, Br, F, cyano; R2 = alkyl, hydroxyalkyl, alkoxyalkyl, (CH2)mOCH2CH2OH; m = 1, 2; R3 = alkyl; R4 = (R6-substituted) (benzo-fused) C-bonded 6-membered heteroaryl containing 1-3 N atoms; R5 = H, alkyl, hydroxyalkyl; R6 = halo, OCF3, cyano, NO2, CONR7R8, NR7R8, OR10, CO2R10, (unsatd.) (R9-substituted) alkyl, etc.; R7, R8 = H, (substituted)

*not smeared
hit*


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
Ph, alkyl, cycloalkyl, etc.; R9 = O, OR10, SR10, halo, NR7R8, CO2R10, etc.; R10 = H, alkyl, cycloalkyl, (substituted) Ph], were prepd. Thus, N-(4-chlorobenzyl)-2-(chloromethyl)-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide (prepn. given), diisopropylethylamine, and 2-(methylamino)-1-pyridin-3-ylethanol hydrobromide were heated in DMF at 90° for 2 h to give N-(4-chlorobenzyl)-2-[[[2-hydroxy-2-(2-pyridin-3-ylethyl) (methylamino)methyl]-7-methyl-4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamide. The latter inhibited HCMV, HSV, and VSV polymerase with IC50 = 0.16, 0.58, and 0.22 µM, resp.

IT 672949-14-3P
RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylethanamines as antiviral agents)

RN 672949-14-3 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo-, (+)- (9CI) (CA INDEX NAME)

Rotation (+).




IT 672949-12-1P 672949-16-5P 672949-18-7P
672949-20-1P 672949-22-3P 672949-24-5P
672949-26-7P 672949-28-9P 672949-30-3P
672949-32-5P 672949-34-7P 672949-36-9P
672949-38-1P 672949-40-5P 672949-42-7P
672949-44-9P 672949-46-1P 672949-48-3P
672949-50-7P 672949-52-9P 672949-54-1P
672949-56-3P 672949-58-5P 672949-60-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroarylethanamines as antiviral agents)

RN 672949-12-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[2-hydroxy-2-(3-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 672949-16-5 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-(4-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-18-7 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-20-1 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672949-22-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[2-hydroxy-2-(6-methyl-2-pyridinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-24-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-(2-quinolinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-26-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672949-34-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-


dihydro-2-[[[2-hydroxy-2-(3-pyridazinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-36-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-

4,7-dihydro-2-[[[2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-38-1 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-ethyl-

4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672949-28-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 672949-30-3 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-32-5 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672949-40-5 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyrimidinyl)ethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)



RN 672949-42-7 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-

dihydro-2-[[[2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo-7-propyl- (9CI) (CA INDEX NAME)




RN 672949-44-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-(2,3-dihydroxypropyl)-4,7-dihydro-2-[[[2-hydroxy-2-(2-pyridinyl)ethyl]methylamino]methyl]-4-oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)




RN 672949-46-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-48-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(3-hydroxypropyl)-2-[[[(2R)-2-hydroxy-2-(2-pyrimidinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)




RN 672949-50-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-(2-hydroxyethyl)-2-[[[(2R)-2-hydroxy-2-(2-pyrimidinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 672949-59-6 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-cyanophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 672949-61-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-bromophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 672950-23-1P 672950-25-3P 672950-27-5P
 672950-29-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

pyridinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672949-52-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-pyrazinylethyl)methylamino)methyl]-7-(2-methoxyethyl)-4-oxo- (9CI) (CA INDEX NAME)



RN 672949-54-1 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-7-[2-(2-hydroxyethoxy)ethyl]-2-[[[(2R)-2-hydroxy-2-pyrazinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 672949-57-4 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-fluorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)


(Reactant or reagent)

(prepn. of heteroarylethanolamines as antiviral agents)

RN 672950-23-1 CAPLUS


CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-7-((2,2-dimethyl-1,3-dioxolan-4-yl)methyl)-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-4-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672950-25-3 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2R)-2-hydroxy-2-(2-pyridinylethyl)methylamino)methyl]-4-oxo-7-[3-[[[tetrahydro-2H-pyran-2-yl]oxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 672950-27-5 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[(2-hydroxy-2-(2-pyrimidinylethyl)methylamino)methyl]-4-oxo-7-[3-[[[tetrahydro-2H-pyran-2-yl]oxy]propyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



RN 672950-29-7 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2R]-2-hydroxy-2-pyrazinylethyl]methylamino]methyl]-4-oxo-7-[[2-[[2-[(tetrahydro-2H-pyran-2-yl)oxy]ethoxy]ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

RN 292144-14-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203665 CAPLUS
 DOCUMENT NUMBER: 140:229446
 TITLE: Method using heterocyclic carboxamide compounds for preventing or treating atherosclerosis or restenosis
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 110 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019939	A1	20040311	WO 2003-US26973	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NS, SN, TD, TG			
US 2004102473	A1	20040527	US 2003-651216	20030828
PRIORITY APPLN. INFO.:			US 2002-407090P	P 20020830

OTHER SOURCE(S): MARPAT 140:229446
 AB The invention provides a method of treating atherosclerosis or restenosis in a mammal which comprises administering an effective amount of a thieno[2,3-b]pyridine carboxamide derivative or a pyrrolo[3,2,1-i]quinoline carboxamide derivative
 IT 292144-13-9 292144-14-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heterocyclic carboxamide compds. for preventing or treating atherosclerosis or restenosis)
 RN 292144-13-9 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)




Phenyl not ket

L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2004:203660 CAPLUS
 DOCUMENT NUMBER: 140:229445
 TITLE: Method using heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis
 INVENTOR(S): Wathen, Michael W.; Wathen, Lynne K.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 190 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004019933	A1	20040311	WO 2003-US26963	20030828
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MN, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LJ, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CP, CG, CI, CM, CA, GN, GQ, GW, ML, MR, NS, SN, TD, TG			
US 2004176366	A1	20040909	US 2003-651290	20030828
PRIORITY APPLN. INFO.:			US 2002-407563P	P 20020830
			US 2003-469630P	P 20030509

OTHER SOURCE(S): MARPAT 140:229445
 AB The invention provides a method of preventing or treating atherosclerosis or restenosis in mammals, which comprises administering an effective amount of a heterocyclic carboxamide.
 IT 292144-14-0
 RL: AGR (Agricultural use); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (heterocyclic carboxamides for preventing or treating atherosclerosis or restenosis)
 RN 292144-14-0 CAPLUS
 CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[[[2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo- (9CI) (CA INDEX NAME)



not ket

REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS


L5 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2002:72315 CAPLUS
DOCUMENT NUMBER: 136:129036
TITLE: Method of screening 4-hydroxyquinolin (4-HQ),
4-oxo-dihydroquinoline (4-oxo-DHQ), and
4-oxo-dihydrothienopyridine (4-oxo-DHTP) derivatives
as non-nucleoside herpesvirus DNA polymerase
inhibitor
INVENTOR(S): Homa, Fred L.; Mathen, Michael W.; Hopkins, Todd A.;
Thomsen, Darrel R.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 126 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002006513	A2	20020124	WO 2001-US16525	20010713
WO 2002006513	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KR, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 2002076789	A1	20020620	US 2001-904065	20010712
US 6682892	B2	20040127		
AU 2001072920	A5	20020130	AU 2001-72920	20010713
US 2004115623	A1	20040617	US 2003-692556	20031024
PRIORITY APPLN. INFO.:			US 2000-218118P	P 20000713
			US 2001-283860P	P 20010413
			US 2001-904065	A3 20010712
			WO 2001-US16525	W 20010713

AB The present invention provides a method for selecting non-nucleoside herpesvirus DNA polymerase inhibitors from 4-HQ, 4-oxo-DHQ, and 4-oxo-DHTP deriva. by measuring IC50. The invention also provides sequences of mutant herpesvirus DNA polymerase genes which resist non-nucleoside inhibitors, and herpesvirus mutant strains containing the drug-resistant DNA polymerase genes. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in need of such treatment. The present invention relates to a method for selecting an anti-herpes viral compound and a method for selectively inhibiting herpesvirus in a human host in

L5 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)
need of such treatment.
IT 292144-14-0
RL: BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(4-HQ, 4-oxo-DHQ, and 4-oxo-DHTP deriva. as non-nucleoside herpesvirus DNA polymerase inhibitor)
RN 292144-14-0 CAPLUS
CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-dihydro-2-[(1,2-hydroxy-2-phenylethyl)methylamino]methyl-7-methyl-4-oxo-(9CI) (CA INDEX NAME)




L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN
ACCESSION NUMBER: 2000:646018 CAPLUS
DOCUMENT NUMBER: 133:222607
TITLE: Preparation of
4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-
5-carboxamides as antiviral agents
INVENTOR(S): Schnute, Mark E.; Cudahy, Michele M.; Scott, Allen
PATENT ASSIGNEE(S): Pharmacia and Upjohn Company, USA
SOURCE: PCT Int. Appl., 95 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000053610	A2	20000914	WO 2000-US5937	20000307
WO 2000053610	A3	20010125		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KR, LS, MM, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2366609	AA	20000914	CA 2000-2366609	20000307
US 6239142	B1	20010529	US 2000-521027	20000307
NZ 513758	A	20010928	NZ 2000-513758	20000307
EP 1159279	A2	20011205	EP 2000-913786	20000307
EP 1159279	B1	20021016		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000008804	A	20020416	BR 2000-8804	20000307
AT 226208	E	20021115	AT 2000-913786	20000307
JP 2002539130	T2	20021119	JP 2000-604046	20000307
ES 2184705	T3	20030416	ES 2000-913786	20000307
AU 759875	B2	20030501	AU 2000-35162	20000307
AU 2000035162	A5	20000928		
TW 222451	B1	20041021	TW 2000-89104265	20000309
US 2003069937	A1	20030117	US 2001-824334	20010402
US 6495683	B2	20021217		
ZA 2001007255	A	20021202	ZA 2001-7255	20010811
NO 2001004363	A	20011108	NO 2001-4363	20010907
PRIORITY APPLN. INFO.:			US 1999-123660P	P 19990309
			US 2000-521027	A3 20000307
			WO 2000-US5937	W 20000307

OTHER SOURCE(S): MARPAT 133:222607
GI

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)



AB The title compds. [I; R1 = Cl, Br, CN, etc.; R2 = H, R5, NR7R8, etc.; R3

=
H, halo, aryl, etc.; R4 = H, halo, alkyl, etc.; R5 = heterocyclyl bound
via a carbon atom, (un)saturated (un)substituted alkyl, (un)saturated
(un)substituted cycloalkyl, etc.; R7, R8 = H, aryl, (un)saturated
(un)substituted alkyl; NR7R8 form a heterocyclyl and their
pharmaceutically acceptable salts, useful in preventing or treating a
herpesvirus infection, were prepared Thus, rescting Et

4-hydroxythieno[2,3-
b]pyridine-5-carboxylate with 4-chlorobenzylamine afforded 45% I [R1 =

Cl;
R2 = H; R3, R4 = H] which showed IC50 of 28.9 μ M against HCMV
polymerase.

IT 292144-13-9P 292144-14-0P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);
BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of

4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxamides as
antiviral agents)

RN 292144-13-9 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-
dihydro-2-[[[2-hydroxy-2-(4-hydroxyphenyl)ethyl]methylamino]methyl]-7-
methyl-4-oxo- (9CI) (CA INDEX NAME)



RN 292144-14-0 CAPLUS

CN Thieno[2,3-b]pyridine-5-carboxamide, N-[(4-chlorophenyl)methyl]-4,7-
dihydro-2-[[[2-hydroxy-2-phenylethyl]methylamino]methyl]-7-methyl-4-oxo-
(9CI) (CA INDEX NAME)

L5 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2005 ACS on STN (Continued)

